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2214-031X/Copyright ª 2013, The Aut
license (http://creativecommons.org/Summary Osteoarthritis (OA) is the most common form of joint disorders, which is the lead-
ing cause of pain and walking disability in older adults. The primary concern of OA is loss of
articular cartilage. Yet the integrity of articular cartilage relies on subchondral bone to provide
mechanical support and nutrition supply. The term “osteo”-arthritis has indicated the impor-
tance of subchondral bone in the pathogenesis and management of knee OA. This review fo-
cuses on the current understanding of subchondral bone pathophysiology in human and
animal models, and discusses how to translate it from bench to bedside for early diagnosis
and intervention of OA.
Copyrightª 2013, The Authors. Published by Elsevier (Singapore) Pte Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Osteoarthritis (OA) is the most prevalent degenerative joint
disorder, mainly afflicting the weight-bearing joints such as
knees and hips. The prevalence of knee OA is approximately
6% of the general population with a prediction of 67 millionoratory Block, Li Ka Shing
, Pokfulam, Hong Kong. Tel.:
.
C. Wen).
.11.004
hors. Published by Elsevier (Singa
licenses/by-nc-nd/4.0/).people in the USA and 100 million people in China by 2020
[1]. It is the leading cause of pain, physical disability, and
poor quality of life in older adults. Patients at the end stage
of OA have to receive arthroplasty surgery, a major oper-
ation with significant morbidities and complications [2].
The clinical demand on surgeries has increased rapidly in
the past 10 years and the average waiting time for arthro-
plasty in Queen Mary Hospital of Hong Kong is now more
than 3 years [2]. The direct cost of surgery is approximately
70,000 HKD/case per year [3]. OA has caused a heavy so-
cioeconomic burden in Hong Kong [3,4]. At present, ther-
apies for early OA are limited to symptom relief such aspore) Pte Ltd. This is an open access article under the CC BY-NC-ND
OA and subchondral bone 17analgesic or joint lubricants [5]. An in-depth understanding
of the pathomechanism and pathophysiology of OA is
essential to develop disease-modifying therapies.
The aetiology of OA is multifactorial. A number of risk
factors have been identified in the pathogenesis of OA such
as ageing, being postmenopausal, obesity, genetic predis-
position, and previous joint injuries [6]. Current therapies
for OA do not target the cause of OA, but aim at preventing
or reserving the structural deterioration of a joint. The
hallmark of OA is loss of articular cartilage, which cushions
the joint during movement. Yet its homeostasis and
integrity relies on the biochemical and biomechanical
interplay with subchondral bone and other joint tissues [7].
Subchondral bone provides the mechanical support and
nutrition supply for overlying articular cartilage, and it
undergoes constant adaptation in response to changes of
the biomechanical environment in the weight-bearing knee
joint such as excessive body weight, weakening muscles
with ageing, or joint instability after previous ligament
injury [8]. Disturbances of subchondral bone such as
osteophytosis, subchondral bone cyst (SBC), and sclerotic
changes are major radiological features of OA. There is
mounting evidence recently suggesting the potential of
some bone active agents such as alendronate and strontium
in the treatment of OA not only in animal models but also in
human models [9,10].
Hence, the aim of this review is to summarise the cur-
rent understanding of and consensus on the role of sub-
chondral bone disturbance in the pathogenesis of OA in
both clinical and preclinical settings. The advantages and
limitations of various animal models to mimic the clinical
features of OA will be discussed to facilitate the knowledge
transfer from bench to bedside.Methods, applications, and limitations of
animal models to mimic cartilage degeneration
Loss of articular cartilage is a primary concern in OA. It is
macroscopically characterised as surface fibrillation, sur-
face discontinuity, vertical fissures, erosion, denudation, or
deformation of cartilage and dropout of articular chon-
drocytes. The collagen meshwork of articular cartilage
becomes stiffened as a result of a gradual loss of water
content and proteoglycan with the ageing process prior to
the onset of OA [11,12]. Such collagen fibrils are susceptible
to damage under physiological mechanical loading in daily
activities. As a consequence, it will trigger the cascade of
inflammatory reaction and activate the reparative process.
A number of inflammatory mediators [complement
component 5 (C5); interleukin-1 (IL-1) or IL-6] [13,14],
downstream signalling [hypoxia-inducible factor-2a (HIF-
2a)] [15e17] and proteinase [matrix metalloproteinase 13
(MMP13); and A disintegrin and metalloproteinase with
thrombospondin motifs-5 (ADAMTS-5)] [18e21], have been
identified in the destructive process of articular cartilage in
OA. Other factors that govern the metabolism of articular
chondrocytes such as parathyroid hormone-related protein
(PTHrP), Indian hedgehog (IHH), and transforming growth
factor-b1 (TGF-b1) signalling pathways have also been
explored in the pathomechanism of OA [22e24]. PTHrP and
IHH signalling are known as the key regulators in the controlof proliferation and hypertrophic differentiation of chon-
drocytes in the growth plate during skeletal development
[25e27]. TGF-b1 is another important signalling protein to
play a part in the maintenance of the integrity of articular
cartilage through repressing hypertrophic changes of
articular chondrocytes [24]. The altered activin receptor-
like kinase 1/5 (ALK1/ALK5) ratio with the activated
TGF-b1 signalling pathway could induce the overexpression
of type X collagen and MMP13 of articular chondrocytes,
and trigger the initiation of OA [28].
Currently, there are a few experimental approaches to
mimic the destructive process of articular cartilage,
including intra-articular injection of enzymes [17,29e33],
physical immobilisation [34], surgical destabilisation
[22,35], and transgenic modification [14,19,23,35,36]. The
intra-articular injection of reagents for OA induction in-
cludes papain Refs. [33], iodoacetate [29], and collagenase
[17,30e32]. These are able to create an acute model to
investigate acute cartilage degradation and significant
joint pain in animals. However, they have obvious limita-
tions as a model for OA. Intra-articular injection of chem-
icals usually induces significant inflammatory reactions and
extensive and rapid chondrocyte death. It contradicts the
features of human OA, such as the chronic course of dis-
ease, low level of inflammation, co-occurrence of chon-
drocyte death and cloning, and prominent subchondral
bone changes.
Physical immobilisation is another approach to induce
OA in animals, for example, rat, rabbit, and dog [34]. An
understanding of the alterations in articular cartilage
following short- and long-term immobilisation is useful for
the optimisation of rehabilitation protocols for patients. It
was reported that the overall thickness of articular carti-
lage in the knee decreases up to 9% after 11 weeks of
immobilisation and the deformation rate under a test load
increases up to 42%. However, the atrophy and necrosis of
articular chondrocytes occurred instead of displaying
chondrocyte cloning in OA cartilage. Studies investigating
subchondral bone changes and its relation with overlying
cartilage degradation in immobilised joints remain lacking.
Surgical destabilisation of joints is the most common
procedure for OA induction [14,17,19,22,23,35,37]. Ante-
rior cruciate ligament transection (ACLT), destabilisation of
medial meniscus (DMM), or combined surgeries has been
widely used. It has been demonstrated that the severity
and progression of OA-like changes is dependent on the
grade of joint instability induced by the types of surgeries
[38]. For example, ACLT induces a relatively mild OA model
showing only partial cartilage destruction at 8 weeks after
surgery, following significant subchondral bone damage in a
mouse model [35]. By contrast, the DMM-induced OA model
is prone to develop significant cartilage destruction with
subsequent osteophyte formation [15e17]. Studies on the
degeneration of articular cartilage commonly employed the
DMM approach rather than the ACLT model.
Transgenic mouse models have also been used in OA
studies. It was reported that the knockout of these struc-
tural proteins in articular cartilage, for example, collagen
type IX, results in the breakdown of the extracellular ma-
trix of hyaline cartilage [39]. Similarly, defective collagen
type I led to structural changes of subchondral bone and
subsequent degradation of articular cartilage in mice [40].
18 C. Wen et al.In addition, the genetic depletion of signalling molecules or
proteinases such as Smad3 [41], HIF-2a [15e17], ADAMTS-5,
and MMP13 [18e21], altering the metabolism of articular
cartilage, is not surprising. The aetiology of OA is multi-
factorial, not simply a genetically determinant disorder,
although genetic contributions to the pathogenesis of OA do
indeed exist, for example, mutation or genetic variation
(e.g., SMAD3) [42e44]. Abnormalities in transgenic mouse
models include problems of growth, not of decay. Trans-
genic mouse models should not be used to recapitulate OA
but can be employed to prove the concept about a certain
cellular or molecular mechanism in the regulation of
cartilage or bone metabolism.
Although significant progress has been made in the un-
derstanding of the mechanism of cartilage degeneration,
few structure-modifying therapies with real clinical impact
are being developed to attenuate or reverse the progressive
deterioration of articular cartilage in OA [22,37]. It has
been recognised that OA is not solely a problem of cartilage
damage but also a whole joint disorder [7,45]. In particular,
articular cartilage and subchondral bone function as a unit
to maintain the structural and functional integrity of the
joint [7]. Thus, animal models to recapitulate the distur-
bance of subchondral bone as well as cartilage degenera-
tion are needed to better understand the cartilage bone
unit in the pathogenesis of OA. Here, we will continue to
discuss the ACLT surgical-induced and spontaneously
occurring OA animal models with prominent subchondral
bone changes, respectively.Pros and cons of ACLT model to recapitulate
subchondral bone disturbance
The importance of subchondral bone disturbance in the
pathomechanism and pathophysiology of OA has been rec-
ognised a long time ago when people named it as “osteo”-
arthritis. There is mounting evidence showing correlations
between radiological findings of subchondral bone distur-
bance and clinical symptoms of OA. For example, bone
marrow lesions (BMLs) are a major radiological finding at
the early stage of OA under magnetic resonance imaging
(MRI) examination. BMLs are an oedema-like lesion, which
was further characterised as sclerotic but less mineralised
bone [46]. It was reported that SBCs develop in the same
region as BMLs [47,48]. The presence of SBCs, in conjunc-
tion with BMLs, is associated with the severity of pain Refs.
[49e51]. They are able to predict tibial cartilage volume
loss and risk of joint replacement surgery in knee OA pa-
tients [52e55]. The occurrence of subchondral cysts may
lead to the increase of osseous pressure [56,57], which in
turn results in sclerotic changes of bone surrounding cystic
lesions according to Wolff’s law. The exact mechanism
underlying subchondral bone pathologies and its relation
with the progression of OA remains largely unknown,
although the aforementioned associations have been iden-
tified [58].
Attempts have been made to investigate the nature of
BMLs in OA. Subchondral BMLs were initially linked with
perfusion abnormalities such as increased vascular perme-
ability and ischaemia [59,60]. Impaired vascular supplies
also affect subchondral bone metabolism and subsequentlyOA [61,62]. BMLs from knee OA were once characterised by
sclerotic bone tissue that was less mineralised [46], which
indicates subchondral osteoblast dysfunction in OA with
overproduction of collagen type I but poor mineralisation
[63]. Defective subchondral osteoblasts produced more in-
flammatory cytokines and mediators, such as IL-1b, IL-6, IL-
8, and TGF-b1 [64]. In addition, the defective subchondral
osteoblasts from OA patients could alter the phenotype of
normal articular chondrocytes towards hypertrophic dif-
ferentiation by decreasing expression of PTHrP, reducing
production of aggrecan, and upregulating MMP13, a major
enzyme in decaying the cartilaginous matrix [64e66]. Fac-
tors that govern subchondral perfusion abnormalities such
as BMLs could be candidate therapeutic targets to treat OA.
To the best of our knowledge, there are few reports that
have identified BMLs in OA animal models until recently,
and this was done in an ACLT mouse model [35].
Rupture of the anterior cruciate ligament (ACL) in-
creases the risk of knee OA, as approximately 20e35% of
these patients are estimated to have had an incidental ACL
tear [67,68]. The ACLT model is a clinical relevant model to
mimic OA secondary to ligament injuries. In response to
joint instability after ligament injury, subchondral bone,
articular cartilage, and other joint tissues undergo a dra-
matic remodelling process and adaptive changes [8]. Sub-
chondral bone remodelling occurred with angiogenesis prior
to microscopic changes in articular cartilage on the poste-
rior tibia in the ACLT mouse model (Fig. 1) [35]. Impor-
tantly, the ACLT model has been reported to present all
types of radiological features similar to human OA, such as
subchondral BMLs [35] and cystic formation [69], in addition
to osteophytosis and sclerosis. Overall, the ACLT model will
fulfil the needs for preclinical studies with subchondral
bone disturbance as a target of structure-modifying thera-
pies for OA. Yet several issues should be taken into
consideration in establishing an ACLT model.
First, the skeletal maturation and anatomic character-
istics of animals should be considered in creating the
models [70]. The age for skeletal of mouse is 10e12 weeks,
whereas it is 9 months in rabbits and 2 years for sheep,
respectively. ACL injuries usually afflict young adults, and
the comparable age in mouse equals 3e6 months old, which
is recommended for model establishment. In addition,
outcomes of the ACLT model also vary in different species,
for example, mouse, rat, and rabbit. Damage of the artic-
ular cartilage usually develops on the posterior site in the
medial compartment of the mouse or rat knee joint, yet it
is present on the lateral side of the knee joints in rabbits
after ACLT surgery. Hence, mouse and rat are preferred for
the ACLT model compared with rabbit.
Second, the gender of animals should also be consid-
ered. It was reported that the severity of OA was markedly
higher in males than females after destabilisation surgery
[71]. Ovariectomy (OVX) mice experienced less OA than
intact males, whereas females after OVX developed
significantly more severe OA than control females [71]. It
suggests that sex hormones play a critical role in the pro-
gression of OA. Ovarian hormones may decrease the
severity of OA in female mice. Male hormones, such as
testosterone, exacerbate OA in male mice. Female mice
might be chosen to induce a relatively slower course of OA
development.
Figure 1 Subchondral bone changes in the anterior cruciate ligament transection (ACLT) mouse model. In comparison to pre-
operation (AeD), significant bone loss (EeH) was present with increased angiogenesis (G) prior to loss of proteoglycan in artic-
ular cartilage at 1 month after surgery. Uncoupled bone resorption with formation led to abnormalities at the subchondral area in
the ACLT model (H). (A,B,E,F: Safranin O staining; C,G: Goldner’s trichrome staining; and D,H: micro-computed tomography images
of tibial plateau of mice joints.)
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hunting [72] and therapeutic efficacy studies for OA
[73e78]. However, we still need to be aware of the major
limitations of the ACLT model. First, the ACLT model should
mimic the secondary OA with a previous history of joint
injury. Yet the majority of human OA is multifactorial and
occurs spontaneously. Moreover, joint instability is not a
sole pathomechanism in the destruction of the joint. The
inflammation post-surgery (injury) also plays an essential
role in the pathogenesis of OA after ACL injury. We should
bear this in mind when we interpret data collected from
the ACLT model.Values and drawbacks of spontaneous
occurring OA models
OA is an age-related disease and develops spontaneously
without an exact cause(s). Such naturally occurring OA has
also been reported in some animals, for example, the
DunkineHartley strain guinea pig and STR/ORT strain
mouse. For example, the natural history of DunkineHartley
guinea pigs has been documented in the literature (Fig. 2).
The naturally occurring OA animal models indeed resemble
the pathophysiological process of human OA in some as-
pects. First, it develops in a chronic course similar to
human OA. Second, subchondral bone disturbance has been
identified as a key element with the progression of OA as
well as overlying cartilage degeneration [59,79e82]. Third,
multiple risk factors, such as ageing, sex hormone, obesity,
impaired blood supply, and ligament laxity have been
found in association with the progression of disease in
DunkineHartley guinea pigs [59,79,81]. Last but not least,
the relatively larger size of the animals favours the analysis
of advanced imaging modalities such as MRI, which might
be easily linked with radiological findings in human OA
[59,60].
Guinea pigs are more closely related to porcupines and
chinchillas rather than to mice and rats; unlike most other
rodents they have no tail. “The laboratory guinea pig was
derived from domesticated stocks of wild guinea pigsoriginated in Peru, South America. Many of the laboratory
strains used today originated with the breeding work by
Dunkin and Hartley since 1926. The DunkineHartley and
Hartley stocks remain the major outbred stocks of guinea
pigs used in the laboratory today. Sewell Wright also
developed a number of the inbred strains of guinea pig for
genetic studies. Of the original 20 or so inbred strains of
guinea pigs, only two remain today, Strains 2 and 13”
(http://www.nus.edu.sg/iacuc/files/The%20Laboratory%
20Guinea%20Pig.pdf). These inbred guinea pigs are now
available in some research institutes in the UK and USA. A
number of laboratory studies have confirmed the occur-
rence of spontaneous knee OA in albino DunkineHartley
guinea pigs [59,79e85]. There is no report, to date, on the
development of knee OA in pigmented (two-colour or
three-colour) guinea pigs, which are also available for
laboratory use as the control group for albino pigs in
mainland China [86]. In the literature, the inbred Strains 2
and 13 guinea pigs are regarded as the OA-resistant model,
which were used as the control group for albino Dun-
kineHartley guinea pigs [79,80,82,85].
Compared with the ACLT model, OA-like changes pro-
gressed slowly in DunkineHartley guinea pigs (Fig. 3). It
was observed that subchondral trabecular bone underwent
significant remodelling with a thickening of calcified carti-
lage in the 6-month-old guinea pigs in comparison with the
3-month-old pigs. Further, the number of articular chon-
drocytes firstly increased along with subchondral bone
remodelling, followed by a dropout with the 12-month-old
pigs with structural deterioration. Such temporal changes
of articular chondrocytes closely resembled our observa-
tions in human OA specimens (Fig. 4).
As previously reported, damage was initially present in
w5-month-old guinea pigs [82,85,86]. Regarding their life-
span (5e8 years) and skeletal maturation (at 6 months old),
it should be considered as an early onset of OA. Genetic and
developmental factors should be prioritised as possible
causes of OA in guinea pigs. However, the genome infor-
mation of guinea pigs remains lacking and there are few
molecular biology tools available for the in-depth under-
standing of its underlying pathomechanism.
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Figure 2 Natural history of spontaneously occurring osteoarthritis in DunkineHartley guinea pigs.
20 C. Wen et al.Integrated approaches for functional and
structural assessments of OA animal models
The Mankin score is the classic histopathological evaluation
tool for grading the severity of OA. Recently, more detailed
grading systems have been proposed and recommended by
the Osteoarthritis Research Society International (OARSI)
for different species of animal models [87e93]. As afore-
mentioned, some radiological features of subchondral bone
disturbance in human OA can be reproduced in animal
models, for example, the ACLT model or guinea pig model.
For example, MRI is a powerful tool to detect the problem
in subchondral perfusion and cystic lesion formation
[59,69,85]. Imaging subchondral bone disturbance in small
animals such as mouse is technically challenging. The 7-T orFigure 3 Temporal changes of knee osteoarthritis in the Dunkine
and C,C0: 12-month-old). The subchondral trabecular bone underwe
6-month-old guinea pigs. Meanwhile, the chondrocyte number dra
Later, the dropout of chondrocytes was observed in the 12-month-
articular surface disruption.11-T MRI modalities and longer scanning time are often
necessary to achieve better single-to-noise ratio with
higher image resolution of the mouse joint. Micro-
computed tomography is another imaging modality to
visualise and quantify subchondral bone mass and micro-
structure ex vivo or in vivo in OA animal models [10]. It was
once used for cartilage imaging with contrast enhancement
[94]. In addition to routine bone parameters, the porosity
of the subchondral plate is an emerging indicator in the
early stage of OA in the ACLT mouse model [10].
Functional assessments are also challenging issues in OA
animal models. Pain assessment in animal models usually
relies on analysis of gait behaviour. However, the sensitivity
and specificity of gait analyses are questionable in the
laboratory setting and their results also need moreHartley guinea pig model (A,A0: 3-month-old; B,B0: 6-month-old;
nt significant loss with a thickening of calcified cartilage in the
matically increased along with subchondral bone remodelling.
old guinea pigs with structural deterioration, characterised by
Figure 4 Histopathological features of human osteoarthritis tibial plateau collected during total knee replacement. On the
lateral tibial plateau (A), the number of articular chondrocytes were randomly scattered and filled the whole thickness of OA
cartilage. By contrast, the number of chondrocytes dramatically decreased with disruption of hyaline cartilage on the medial tibial
plateau (B) in the same patient.
OA and subchondral bone 21validation. Atomic force microscopy and nanoindentation is
an emerging nanomechanical tool for early detection of
nanoscopic changes of articular cartilage at the onset of OA
[11,12].Potential use of bone drugs as OA therapies
Subchondral bone undergoes constant remodelling in
response to mechanical loading of weight-bearing joints
during life. A complete cycle of bone remodelling comprises
osteoclast-mediated bone resorption and osteoblast-
mediated bone formation [95]. In brief, bone resorption
will release and reactivate a number of cytokines
embedded in the bone matrix such as TGF-b1 and insulin-
like growth factor 1 [73,96]; it will be followed by the
recruitment of mesenchymal stem cells (MSCs) from bone
marrow to resorption pits and then on to differentiate into
osteoblasts for bone formation [97].
The key radiological features of OA such as BMLs (scle-
rotic bone but less mineralised) [46] and cyst formation [98]
indicate the presence of uncoupled subchondral bone
remodelling. The previously assumed primary osteoblastic
dysfunction [63,64,99] is highly likely a result of uncoupled
bone remodelling. Therefore, factors that govern the cycle
of bone remodelling could be candidates of OA therapies in
order to break the vicious cycle of uncoupled bone remod-
elling. Inhibition of osteoclastogenesis and osteoclast-
mediated bone resorption has been proven to be an effec-
tive approach to alleviate subchondral bone disturbance
and the severity of OA [9,100e106]. Alendronate, having
two phosphonate (PO3) groups and a similar structure to
pyrophosphate [107], can inhibit subchondral bone loss by
encouraging osteoclasts to undergo apoptosis, at the early
stage of OA [10,104e106]. Moreover, cathepsin K is
responsible for the degradation of type I collagen in
osteoclast-mediated bone resorption. Inhibitors of
cathepsin K were also able to treat OA in a preclinical
setting [108,109]. The OPG/RANKL system plays a pivotal
role in osteoclastogenesis, which has also been implicated in
the pathogenesis of OA [110]. Strontium can modulate the
OPG/RANKL ratio and potentially serve as a disease-
modifying drug for OA [9,100e102]. These drugs wereusually used for osteoporosis treatment in an attempt to
correct uncoupled bone remodelling and to restore the
balance between bone resorption and new bone formation.
Both osteoporosis and osteoarthritis share the common
feature of uncoupled bone remodelling. However, osteo-
porosis shows progressive bone loss, whereas osteoarthritis
presents transient bone loss followed by uncontrolled bone
formation. Thus, anti-osteoporosis drugs could be used to
treat OA at the phase of bone loss during disease
progression.
The process of MSC recruitment and differentiation
could be another target to maintain the balance of sub-
chondral bone remodelling. It was reported that the large-
scale CD271þ mesenchymal progenitors, having enhanced
chondrogenic and osteogenic potentials [111,112], have
been identified in subchondral bone in human OA [113].
Such progenitors from subchondral bone have also been
isolated from OA cartilage [114,115]. TGF-b1 is a known
growth factor to recruit MSCs to couple bone resorption
with formation [73]. Pharmaceutical or genetic regulation
of TGF-b1 signalling in nestinþ MSCs could attenuate the
severity of OA in an ACLT mouse model [35].
Biological relation of subchondral bone
disturbance in OA with systemic metabolic
disorders
Metabolic syndrome including hypertension and type 2
diabetes mellitus (T2DM) are frequently encountered
comorbidities in elderly patients with knee OA. It has been
reported that approximately 55% of knee OA patients over
65 years old have hypertension and 13% are T2DM [116].
Hence, recently, there is growing research interest
regarding the role of metabolic syndrome in the patho-
mechanism of knee OA among elderly persons [117]. The
intimate relation between knee OA and metabolic syn-
drome significantly contributes to the mortality of patients
compared with the general population [93]. The walking
disabilities of people with OA knees have been identified as
a major risk factor for the death of elderly patients with
T2DM and cardiovascular diseases [93]. Although athero-
matous vascular disease and diabetes were once speculated
22 C. Wen et al.in the pathogenesis of OA [61,62,118], the exact impact of
these comorbidities, such as hypertension and T2DM, on the
severity of knee OA and the progression of disease remains
to be elucidated [119]. As previously reported, high blood
pressure was associated with low bone mass and high risk of
fractures in elderly persons [120e122]. In T2DM patients,
bone quality was also reduced with high risk of fracture
[123], yet bone mineral density increased in the lumbar
spine, hip, and radius in patients [124]. There is a research
gap whether hypertension and T2DM as comorbid diseases
would interfere with subchondral bone remodelling and
aggravate the progression of OA [117,125].Concluding remarks
The ideal animal model should recapitulate pathological
features of human OA. The purpose of animal studies in a
preclinical setting usually include: (1) exploring the struc-
tureefunction relationship in the pathophysiology of OA,
(2) searching for biomarkers at an early stage of disease for
diagnosis of OA, and (3) testing the efficacy of therapies in
prevention and treatment of OA. However, none of the
animal models can reproduce all the pathological features
of OA. The choice of cartilage-centred or bone-centred
animal models will inevitably bring a bias in laboratory data
interpretation and affect knowledge transfer from bench to
bedside. The in-depth understanding of subchondral bone
disturbance in OA will lead to a paradigm shift in therapies
for OA. The ACLT model and the DunkineHartley albino
guinea pig model are recommended in preclinical studies on
subchondral bone pathologies in the search for biomarkers
and drug discovery. Integrated assessment approaches with
advanced imaging modalities should be adopted to provide
more comprehensive and convincing data for translational
OA research. In the near future, contributions of metabolic
risk factor(s) to subchondral bone disturbance in OA should
be investigated further.Conflicts of interest
The authors declare that they have no conflicts of interest.Acknowledgements
The authors acknowledge support from the Li Shu Fan
Medical Foundation, the National Science Foundation of
China (NSFC 81270967#) and the Shenzhen Peacock Project.References
[1] Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Rheum
Dis Clin North Am 2008;34:515e29.
[2] Yan CH, Chiu KY, Ng FY. Total knee arthroplasty for primary
knee osteoarthritis: changing pattern over the past 10 years.
Hong Kong Med J 2011;17:20e5.
[3] Woo J, Lau E, Lau CS, Lee P, Zhang J, Kwok T, et al. Socio-
economic impact of osteoarthritis in Hong Kong: utilization
of health and social services, and direct and indirect costs.
Arthritis Rheum 2003;49:526e34.[4] Woo J, Lau E, Lee P, Kwok T, Lau WC, Chan C, et al. Impact of
osteoarthritis on quality of life in a Hong Kong Chinese pop-
ulation. J Rheumatol 2004;31:2433e8.
[5] Arden NK, Leyland KM. Osteoarthritis year 2013 in review:
clinical. Osteoarthritis Cartilage 2013;21:1409e13.
[6] Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin
Geriatr Med 2010;26:355e69.
[7] Lories RJ, Luyten FP. The bone-cartilage unit in osteoar-
thritis. Nat Rev Rheumatol 2011;7:43e9.
[8] Madry H, van Dijk CN, Mueller-Gerbl M. The basic science of
the subchondral bone. Knee Surg Sports Traumatol Arthrosc
2010;18:419e33.
[9] Murphy CL, Murphy E, Duffy T, O’Sullivan M, Barry M. Efficacy
and safety of strontium ranelate in the treatment of knee
osteoarthritis: results of a double-blind, randomised
placebo-controlled trial. Ann Rheum Dis 2013;72:e13.
[10] Jones MD, Tran CW, Li G, Maksymowych WP, Zernicke RF,
Doschak MR. In vivo microfocal computed tomography and
micro-magnetic resonance imagingevaluationof antiresorptive
and anti-inflammatory drugs as preventive treatments of
osteoarthritis in the rat. Arthritis Rheum 2010;62:2726e35.
[11] Wen CY, Wu CB, Tang B, Wang T, Yan CH, Lu WW, et al.
Collagen fibril stiffening in osteoarthritic cartilage of human
beings revealed by atomic force microscopy. Osteoarthritis
Cartilage 2012;20:916e22.
[12] Stolz M, Gottardi R, Raiteri R, Miot S, Martin I, Imer R, et al.
Early detection of aging cartilage and osteoarthritis in mice
and patient samples using atomic force microscopy. Nat
Nanotechnol 2009;4:186e92.
[13] Ho MC, Lo AC, Kurihara H, Yu AC, Chung SS, Chung SK.
Endothelin-1 protects astrocytes from hypoxic/ischemic
injury. FASEB J 2001;15:618e26.
[14] Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ,
Larsen DM, et al. Identification of a central role for com-
plement in osteoarthritis. Nat Med 2011;17:1674e9.
[15] Ryu JH, Shin Y, Huh YH, Yang S, Chun CH, Chun JS. Hypoxia-
inducible factor-2a regulates Fas-mediated chondrocyte
apoptosis during osteoarthritic cartilage destruction. Cell
Death Differ 2012;19:440e50.
[16] Ryu JH, Yang S, Shin Y, Rhee J, Chun CH, Chun JS. Inter-
leukin-6 plays an essential role in hypoxia-inducible factor
2a-induced experimental osteoarthritic cartilage destruction
in mice. Arthritis Rheum 2011;63:2732e43.
[17] Yang S, Kim J, Ryu JH, Oh H, Chun CH, Kim BJ, et al. Hypoxia-
inducible factor-2a is a catabolic regulator of osteoarthritic
cartilage destruction. Nat Med 2010;16:687e93.
[18] Saleh AS, Najjar SS, Muller DC, Shetty V, Ferrucci L,
Gelber AC, et al. Arterial stiffness and hand osteoarthritis: a
novel relationship? Osteoarthritis Cartilage 2007;15:357e61.
[19] Echtermeyer F, Bertrand J, Dreier R, Meinecke I,
Neugebauer K, Fuerst M, et al. Syndecan-4 regulates
ADAMTS-5 activation and cartilage breakdown in osteoar-
thritis. Nat Med 2009;15:1072e6.
[20] Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T,
Ma HL, et al. Deletion of active ADAMTS5 prevents cartilage
degradation in a murine model of osteoarthritis. Nature
2005;434:644e8.
[21] Neuhold LA, Killar L, Zhao W, Sung ML, Warner L, Kulik J,
et al. Postnatal expression in hyaline cartilage of constitu-
tively active human collagenase-3 (MMP-13) induces osteo-
arthritis in mice. J Clin Invest 2001;107:35e44.
[22] Sampson ER, Hilton MJ, Tian Y, Chen D, Schwarz EM,
Mooney RA, et al. Teriparatide as a chondroregenerative
therapy for injury-induced osteoarthritis. Sci Transl Med 2011;
3:101ra93.
[23] Lin AC, Seeto BL, Bartoszko JM, Khoury MA, Whetstone H,
Ho L, et al. Modulating hedgehog signaling can attenuate the
severity of osteoarthritis. Nat Med 2009;15:1421e5.
OA and subchondral bone 23[24] Yang X, Chen L, Xu X, Li C, Huang C, Deng CX. TGF-b/Smad3
signals repress chondrocyte hypertrophic differentiation and
are required for maintaining articular cartilage. J Cell Biol
2001;153:35e46.
[25] Hirai T, Chagin AS, Kobayashi T, Mackem S, Kronenberg HM.
Parathyroid hormone/parathyroid hormone-related protein
receptor signaling is required for maintenance of the growth
plate in postnatal life. Proc Natl Acad Sci USA 2011;108:
191e6.
[26] Kobayashi T, Soegiarto DW, Yang Y, Lanske B, Schipani E,
McMahon AP, et al. Indian hedgehog stimulates peri-
articular chondrocyte differentiation to regulate growth
plate length independently of PTHrP. J Clin Invest 2005;
115:1734e42.
[27] Kronenberg HM. Developmental regulation of the growth
plate. Nature 2003;423:332e6.
[28] Blaney Davidson EN, Remst DF, Vitters EL, van Beuningen HM,
Blom AB, Goumans MJ, et al. Increase in ALK1/ALK5 ratio as a
cause for elevated MMP-13 expression in osteoarthritis in
humans and mice. J Immunol 2009;182:7937e45.
[29] Janusz MJ, Little CB, King LE, Hookfin EB, Brown KK,
Heitmeyer SA, et al. Detection of aggrecanase- and MMP-
generated catabolic neoepitopes in the rat iodoacetate
model of cartilage degeneration. Osteoarthritis Cartilage
2004;12:720e8.
[30] van den Berg WB, van Osch GJ, van der Kraan PM, van
Beuningen HM. Cartilage destruction and osteophytes in
instability-induced murine osteoarthritis: role of TGFb in
osteophyte formation? Agents Actions 1993;40:215e9.
[31] Scharstuhl A, Glansbeek HL, van Beuningen HM, Vitters EL,
van der Kraan PM, van den Berg WB. Inhibition of endogenous
TGF-b during experimental osteoarthritis prevents osteo-
phyte formation and impairs cartilage repair. J Immunol
2002;169:507e14.
[32] Blaney Davidson EN, Vitters EL, van Beuningen HM, van de
Loo FA, van den Berg WB, van der Kraan PM. Resemblance of
osteophytes in experimental osteoarthritis to transforming
growth factor b-induced osteophytes: limited role of bone
morphogenetic protein in early osteoarthritic osteophyte
formation. Arthritis Rheum 2007;56:4065e73.
[33] Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB.
Reduction of osteophyte formation and synovial thickening
by adenoviral overexpression of transforming growth factor
b/bone morphogenetic protein inhibitors during experi-
mental osteoarthritis. Arthritis Rheum 2003;48:3442e51.
[34] Vanwanseele B, Lucchinetti E, Stussi E. The effects of
immobilization on the characteristics of articular cartilage:
current concepts and future directions. Osteoarthritis
Cartilage 2002;10:408e19.
[35] Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, et al. Inhi-
bition of TGF-b signaling in mesenchymal stem cells of sub-
chondral bone attenuates osteoarthritis. Nat Med 2013;19:
704e12.
[36] Saito T, Fukai A, Mabuchi A, Ikeda T, Yano F, Ohba S, et al.
Transcriptional regulation of endochondral ossification by
HIF-2a during skeletal growth and osteoarthritis develop-
ment. Nat Med 2010;16:678e86.
[37] Johnson K, Zhu S, Tremblay MS, Payette JN, Wang J,
Bouchez LC, et al. A stem cell-based approach to cartilage
repair. Science 2012;336:717e21.
[38] Kamekura S, Hoshi K, Shimoaka T, Chung U, Chikuda H,
Yamada T, et al. Osteoarthritis development in novel
experimental mouse models induced by knee joint insta-
bility. Osteoarthritis Cartilage 2005;13:632e41.
[39] Fassler R, Schnegelsberg PN, Dausman J, Shinya T,
Muragaki Y, McCarthy MT, et al. Mice lacking a1 (IX) collagen
develop noninflammatory degenerative joint disease. Proc
Natl Acad Sci USA 1994;91:5070e4.[40] Blair-Levy JM, Watts CE, Fiorentino NM, Dimitriadis EK,
Marini JC, Lipsky PE. A type I collagen defect leads to rapidly
progressive osteoarthritis in a mouse model. Arthritis Rheum
2008;58:1096e106.
[41] Wu Q, Kim KO, Sampson ER, Chen D, Awad H, O’Brien T, et al.
Induction of an osteoarthritis-like phenotype and degrada-
tion of phosphorylated Smad3 by Smurf2 in transgenic mice.
Arthritis Rheum 2008;58:3132e44.
[42] Yao JY, Wang Y, An J, Mao CM, Hou N, Lv YX, et al. Mutation
analysis of the Smad3 gene in human osteoarthritis. Eur J
Hum Genet 2003;11:714e7.
[43] van de Laar IM, van der Linde D, Oei EH, Bos PK, Bessems JH,
Bierma-Zeinstra SM, et al. Phenotypic spectrum of the
SMAD3-related aneurysms-osteoarthritis syndrome. J Med
Genet 2012;49:47e57.
[44] Valdes AM, Spector TD, Tamm A, Kisand K, Doherty SA,
Dennison EM, et al. Genetic variation in the SMAD3 gene is
associated with hip and knee osteoarthritis. Arthritis Rheum
2010;62:2347e52.
[45] Suri S, Walsh DA. Osteochondral alterations in osteoarthritis.
Bone 2012;51:204e11.
[46] Hunter DJ, Gerstenfeld L, Bishop G, Davis AD, Mason ZD,
Einhorn TA, et al. Bone marrow lesions from osteoarthritis
knees are characterized by sclerotic bone that is less well
mineralized. Arthritis Res Ther 2009;11:R11.
[47] Crema MD, Roemer FW, Zhu Y, Marra MD, Niu J, Zhang Y,
et al. Subchondral cyst-like lesions develop longitudinally in
areas of bone marrow edema-like lesions in patients with or
at risk for knee osteoarthritis: detection with MR imaging e
the MOST study. Radiology 2010;256:855e62.
[48] Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH,
Franklin BA, et al. Diagnosis and management of the meta-
bolic syndrome: an American Heart Association/National
Heart, Lung, and blood institute Scientific statement. Cir-
culation 2005;112:2735e52.
[49] Link TM, Steinbach LS, Ghosh S, Ries M, Lu Y, Lane N, et al.
Osteoarthritis: MR imaging findings in different stages of
disease and correlation with clinical findings. Radiology
2003;226:373e81.
[50] Xu L, Hayashi D, Roemer FW, Felson DT, Guermazi A. Mag-
netic resonance imaging of subchondral bone marrow lesions
in association with osteoarthritis. Semin Arthritis Rheum
2012;42:105e18.
[51] Torres L, Dunlop DD, Peterfy C, Guermazi A, Prasad P,
Hayes KW, et al. The relationship between specific tissue
lesions and pain severity in persons with knee osteoarthritis.
Osteoarthritis Cartilage 2006;14:1033e40.
[52] Tanamas S, Hanna FS, Cicuttini FM, Wluka AE, Berry P,
Urquhart DM. Does knee malalignment increase the risk of
development and progression of knee osteoarthritis? A sys-
tematic review. Arthritis Rheum 2009;61:459e67.
[53] Yusuf E, Kortekaas MC, Watt I, Huizinga TW, Kloppenburg M.
Do knee abnormalities visualised on MRI explain knee pain in
knee osteoarthritis? A systematic review. Ann Rheum Dis
2011;70:60e7.
[54] Tanamas SK, Wluka AE, Pelletier JP, Martel-Pelletier J,
Abram F, Wang Y, et al. The association between subchondral
bone cysts and tibial cartilage volume and risk of joint
replacement in people with knee osteoarthritis: a longitu-
dinal study. Arthritis Res Ther 2010;12:R58.
[55] Hunter DJ, Zhang Y, Niu J, Goggins J, Amin S, LaValley MP,
et al. Increase in bone marrow lesions associated with
cartilage loss: a longitudinal magnetic resonance imaging
study of knee osteoarthritis. Arthritis Rheum 2006;54:
1529e35.
[56] McErlain DD, Milner JS, Ivanov TG, Jencikova-Celerin L,
Pollmann SI, Holdsworth DW. Subchondral cysts create
increased intra-osseous stress in early knee OA: a finite
24 C. Wen et al.element analysis using simulated lesions. Bone 2011;48:
639e46.
[57] Durr HD, Martin H, Pellengahr C, Schlemmer M, Maier M,
Jansson V. The cause of subchondral bone cysts in osteo-
arthrosis: a finite element analysis. Acta Orthop Scand 2004;
75:554e8.
[58] Seah S, Wheaton D, Li L, Dyke JP, Talmo C, Harvey WF, et al.
The relationship of tibial bone perfusion to pain in knee
osteoarthritis. Osteoarthritis Cartilage 2012;20:1527e33.
[59] Lee JH, Dyke JP, Ballon D, Ciombor DM, Rosenwasser MP,
Aaron RK. Subchondral fluid dynamics in a model of osteo-
arthritis: use of dynamic contrast-enhanced magnetic reso-
nance imaging. Osteoarthritis Cartilage 2009;17:1350e5.
[60] Aaron RK, Dyke JP, Ciombor DM, Ballon D, Lee J, Jung E,
et al. Perfusion abnormalities in subchondral bone associated
with marrow edema, osteoarthritis, and avascular necrosis.
Ann N Y Acad Sci 2007;1117:124e37.
[61] Findlay DM. Vascular pathology and osteoarthritis. Rheuma-
tology (Oxford) 2007;46:1763e8.
[62] Conaghan PG, Vanharanta H, Dieppe PA. Is progressive
osteoarthritis an atheromatous vascular disease? Ann Rheum
Dis 2005;64:1539e41.
[63] Couchourel D, Aubry I, Delalandre A, Lavigne M, Martel-
Pelletier J, Pelletier JP, et al. Altered mineralization of
human osteoarthritic osteoblasts is attributable to abnormal
type I collagen production. Arthritis Rheum 2009;60:
1438e50.
[64] Sanchez C, Deberg MA, Bellahcene A, Castronovo V, Msika P,
Delcour JP, et al. Phenotypic characterization of osteoblasts
from the sclerotic zones of osteoarthritic subchondral bone.
Arthritis Rheum 2008;58:442e55.
[65] Sanchez C, Deberg MA, Piccardi N, Msika P, Reginster JY,
Henrotin YE. Subchondral bone osteoblasts induce pheno-
typic changes in human osteoarthritic chondrocytes. Osteo-
arthritis Cartilage 2005;13:988e97.
[66] Sanchez C, Deberg MA, Piccardi N, Msika P, Reginster JY,
Henrotin YE. Osteoblasts from the sclerotic subchondral
bone downregulate aggrecan but upregulate metal-
loproteinases expression by chondrocytes. This effect is
mimicked by interleukin-6, -1b and oncostatin M pre-treated
non-sclerotic osteoblasts. Osteoarthritis Cartilage 2005;13:
979e87.
[67] Amin S, Guermazi A, Lavalley MP, Niu J, Clancy M, Hunter DJ,
et al. Complete anterior cruciate ligament tear and the risk
for cartilage loss and progression of symptoms in men and
women with knee osteoarthritis. Osteoarthritis Cartilage
2008;16:897e902.
[68] Hill CL, Seo GS, Gale D, Totterman S, Gale ME, Felson DT.
Cruciate ligament integrity in osteoarthritis of the knee.
Arthritis Rheum 2005;52:794e9.
[69] McErlain DD, Ulici V, Darling M, Gati JS, Pitelka V, Beier F,
et al. An in vivo investigation of the initiation and progression
of subchondral cysts in a rodent model of secondary osteo-
arthritis. Arthritis Res Ther 2012;14:R26.
[70] Poole R, Blake S, Buschmann M, Goldring S, Laverty S,
Lockwood S, et al. Recommendations for the use of pre-
clinical models in the study and treatment of osteoarthritis.
Osteoarthritis Cartilage 2010;18(Suppl 3):S10e6.
[71] Ma HL, Blanchet TJ, Peluso D, Hopkins B, Morris EA,
Glasson SS. Osteoarthritis severity is sex dependent in a
surgical mouse model. Osteoarthritis Cartilage 2007;15:
695e700.
[72] Fahlgren A, Andersson B, Messner K. TGF-b1 as a prognostic
factor in the process of early osteoarthrosis in the rabbit
knee. Osteoarthritis Cartilage 2001;9:195e202.
[73] Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, et al. TGF-b1-
induced migration of bone mesenchymal stem cells couples
bone resorption with formation. Nat Med 2009;15:757e65.[74] Wu X, Pang L, Lei W, Lu W, Li J, Li Z, et al. Inhibition of Sca-1-
positive skeletal stem cell recruitment by alendronate blunts
the anabolic effects of parathyroid hormone on bone
remodeling. Cell Stem Cell 2010;7:571e80.
[75] Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL,
Smith MD, et al. Tanezumab for the treatment of pain from
osteoarthritis of the knee. N Engl J Med 2010;363:1521e31.
[76] DeGroot J, Bank RA, Tchetverikov I, Verzijl N, TeKoppele JM.
Molecular markers for osteoarthritis: the road ahead. Curr
Opin Rheumatol 2002;14:585e9.
[77] Wen CY, Yan CH, Chung SK, Chiu KY. Development of
osteoarthritis-like changes in transgenic endothelin-1 over-
expressed mice. In: Emoto N, Miyauchi T, editors. The Thir-
teen International Conference on Endothelin. Tokyo, Japan:
Elsevier; 2013. p. 50.
[78] Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH. The
relationship between osteoarthritis and cardiovascular dis-
ease in a population health survey: a cross-sectional study.
BMJ Open 2013;3:e002624.
[79] Quasnichka HL, Anderson-MacKenzie JM, Tarlton JF, Sims TJ,
Billingham ME, Bailey AJ. Cruciate ligament laxity and
femoral intercondylar notch narrowing in early-stage knee
osteoarthritis. Arthritis Rheum 2005;52:3100e9.
[80] Muraoka T, Hagino H, Okano T, Enokida M, Teshima R. Role of
subchondral bone in osteoarthritis development: a compar-
ative study of two strains of guinea pigs with and without
spontaneously occurring osteoarthritis. Arthritis Rheum
2007;56:3366e74.
[81] Ding M, Danielsen CC, Hvid I. Age-related three-dimensional
microarchitectural adaptations of subchondral bone tissues
in guinea pig primary osteoarthrosis. Calcif Tissue Int 2006;
78:113e22.
[82] Anderson-MacKenzie JM, Quasnichka HL, Starr RL, Lewis EJ,
Billingham ME, Bailey AJ. Fundamental subchondral bone
changes in spontaneous knee osteoarthritis. Int J Biochem
Cell Biol 2005;37:224e36.
[83] Bendele AM. Animal models of osteoarthritis. J Musculoskelet
Neuronal Interact 2001;1:363e76.
[84] Bendele AM. Animal models of osteoarthritis in an era of
molecular biology. J Musculoskelet Neuronal Interact 2002;2:
501e3.
[85] Jimenez PA, Glasson SS, Trubetskoy OV, Haimes HB. Spon-
taneous osteoarthritis in Dunkin Hartley guinea pigs: histo-
logic, radiologic, and biochemical changes. Lab Anim Sci
1997;47:598e601.
[86] Wang T, Wen CY, Yan CH, Lu WW, Chiu KY. Spatial and
temporal changes of subchondral bone proceed to micro-
scopic articular cartilage degeneration in guinea pigs with
spontaneous osteoarthritis. Osteoarthritis Cartilage 2013;21:
574e81.
[87] McIlwraith CW, Frisbie DD, Kawcak CE, Fuller CJ, Hurtig M,
Cruz A. The OARSI histopathology initiative e recommenda-
tions for histological assessments of osteoarthritis in the
horse. Osteoarthritis Cartilage 2010;18(Suppl 3):S93e105.
[88] Little CB, Smith MM, Cake MA, Read RA, Murphy MJ, Barry FP.
The OARSI histopathology initiative e recommendations for
histological assessments of osteoarthritis in sheep and goats.
Osteoarthritis Cartilage 2010;18(Suppl 3):S80e92.
[89] Cook JL, Kuroki K, Visco D, Pelletier JP, Schulz L, Lafeber FP.
The OARSI histopathology initiative e recommendations for
histological assessments of osteoarthritis in the dog. Osteo-
arthritis Cartilage 2010;18(Suppl 3):S66e79.
[90] Laverty S, Girard CA, Williams JM, Hunziker EB, Pritzker KP.
The OARSI histopathology initiative e recommendations for
histological assessments of osteoarthritis in the rabbit.
Osteoarthritis Cartilage 2010;18(Suppl 3):S53e65.
[91] Kraus VB, Huebner JL, DeGroot J, Bendele A. The OARSI
histopathology initiative e recommendations for histological
OA and subchondral bone 25assessments of osteoarthritis in the guinea pig. Osteoarthritis
Cartilage 2010;18(Suppl 3):S35e52.
[92] Gerwin N, Bendele AM, Glasson S, Carlson CS. The OARSI
histopathology initiative e recommendations for histological
assessments of osteoarthritis in the rat. Osteoarthritis
Cartilage 2010;18(Suppl 3):S24e34.
[93] Glasson SS, Chambers MG. Van Den Berg WB, Little CB. The
OARSI histopathology initiative e recommendations for his-
tological assessments of osteoarthritis in the mouse. Osteo-
arthritis Cartilage 2010;18(Suppl 3):S17e23.
[94] Xie L, Lin AS, Levenston ME, Guldberg RE. Quantitative
assessment of articular cartilage morphology via EPIC-
microCT. Osteoarthritis Cartilage 2009;17:313e20.
[95] Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA.
Local communication on and within bone controls bone
remodeling. Bone 2009;44:1026e33.
[96] Xian L, Wu X, Pang L, Lou M, Rosen CJ, Qiu T, et al. Matrix
IGF-1 maintains bone mass by activation of mTOR in
mesenchymal stem cells. Nat Med 2012;18:1095e101.
[97] Park D, Spencer JA, Koh BI, Kobayashi T, Fujisaki J,
Clemens TL, et al. Endogenous bone marrow MSCs are dy-
namic, fate-restricted participants in bone maintenance and
regeneration. Cell Stem Cell 2012;10:259e72.
[98] Chiba K, Nango N, Kubota S, Okazaki N, Taguchi K, Osaki M,
et al. Relationship between microstructure and degree of
mineralization in subchondral bone of osteoarthritis: a syn-
chrotron radiation microCT study. J Bone Miner Res 2012;27:
1511e7.
[99] Hilal G, Massicotte F, Martel-Pelletier J, Fernandes JC,
Pelletier JP, Lajeunesse D. Endogenous prostaglandin E2 and
insulin-like growth factor 1 can modulate the levels of
parathyroid hormone receptor in human osteoarthritic os-
teoblasts. J Bone Miner Res 2001;16:713e21.
[100] Alexandersen P, Karsdal MA, Qvist P, Reginster JY,
Christiansen C. Strontium ranelate reduces the urinary level
of cartilage degradation biomarker CTX-II in postmenopausal
women. Bone 2007;40:218e22.
[101] Henrotin Y, Labasse A, Zheng SX, Galais P, Tsouderos Y,
Crielaard JM, et al. Strontium ranelate increases cartilage
matrix formation. J Bone Miner Res 2001;16:299e308.
[102] Tat SK, Pelletier JP, Mineau F, Caron J, Martel-Pelletier J.
Strontium ranelate inhibits key factors affecting bone
remodeling in human osteoarthritic subchondral bone oste-
oblasts. Bone 2011;49:559e67.
[103] Nielsen RH, Bay-Jensen AC, Byrjalsen I, Karsdal MA. Oral
salmon calcitonin reduces cartilage and bone pathology in an
osteoarthritis rat model with increased subchondral bone
turnover. Osteoarthritis Cartilage 2011;19:466e73.
[104] Carbone LD, Nevitt MC, Wildy K, Barrow KD, Harris F,
Felson D, et al. The relationship of antiresorptive drug use to
structural findings and symptoms of knee osteoarthritis.
Arthritis Rheum 2004;50:3516e25.
[105] Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A,
Destefano J, et al. The role of subchondral bone remodeling
in osteoarthritis: reduction of cartilage degeneration and
prevention of osteophyte formation by alendronate in the rat
anterior cruciate ligament transection model. Arthritis
Rheum 2004;50:1193e206.
[106] Neogi T, Nevitt MC, Ensrud KE, Bauer D, Felson DT. The effect
of alendronate on progression of spinal osteophytes and disc-
space narrowing. Ann Rheum Dis 2008;67:1427e30.
[107] Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast
formation and long-term oral bisphosphonate therapy. N Engl
J Med 2009;360:53e62.
[108] Hayami T, Zhuo Y, Wesolowski GA, Pickarski M, Duongle T.
Inhibition of cathepsin K reduces cartilage degeneration in
the anterior cruciate ligament transection rabbit and murine
models of osteoarthritis. Bone 2012;50:1250e9.[109] Kozawa E, Nishida Y, Cheng XW, Urakawa H, Arai E,
Futamura N, et al. Osteoarthritic change is delayed in a Ctsk-
knockout mouse model of osteoarthritis. Arthritis Rheum
2012;64:454e64.
[110] Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-
Pelletier J. New perspective in osteoarthritis: the OPG and
RANKL system as a potential therapeutic target? Keio J Med
2009;58:29e40.
[111] Arufe MC, De la Fuente A, Fuentes I, de Toro FJ, Blanco FJ.
Chondrogenic potential of subpopulations of cells expressing
mesenchymal stem cell markers derived from human syno-
vial membranes. J Cell Biochem 2010;111:834e45.
[112] Cox G, Boxall SA, Giannoudis PV, Buckley CT, Roshdy T,
Churchman SM, et al. High abundance of CD271þ multipo-
tential stromal cells (MSCs) in intramedullary cavities of long
bones. Bone 2012;50:510e7.
[113] Jones E, English A, Churchman SM, Kouroupis D, Boxall SA,
Kinsey S, et al. Large-scale extraction and characterization
of CD271þ multipotential stromal cells from trabecular bone
in health and osteoarthritis: implications for bone regener-
ation strategies based on uncultured or minimally cultured
multipotential stromal cells. Arthritis Rheum 2010;62:
1944e54.
[114] Grogan SP, Miyaki S, Asahara H, D’Lima DD, Lotz MK.
Mesenchymal progenitor cell markers in human articular
cartilage: normal distribution and changes in osteoarthritis.
Arthritis Res Ther 2009;11:R85.
[115] Koelling S, Kruegel J, Irmer M, Path JR, Sadowski B, Miro X,
et al. Migratory chondrogenic progenitor cells from repair
tissue during the later stages of human osteoarthritis. Cell
Stem Cell 2009;4:324e35.
[116] Singh G, Miller JD, Lee FH, Pettitt D, Russell MW. Prevalence
of cardiovascular disease risk factors among US adults with
self-reported osteoarthritis: data from the Third National
Health and Nutrition Examination Survey. Am J Manag Care
2002;8:S383e91.
[117] Zhuo Q, Yang W, Chen J, Wang Y. Metabolic syndrome meets
osteoarthritis. Nat Rev Rheumatol 2012;8:729e37.
[118] Berenbaum F. Diabetes-induced osteoarthritis: from a new
paradigm to a new phenotype. Postgrad Med J 2012;88:
240e2.
[119] Yoshimura N, Muraki S, Oka H, Tanaka S, Kawaguchi H,
Nakamura K, et al. Accumulation of metabolic risk factors
such as overweight, hypertension, dyslipidaemia, and
impaired glucose tolerance raises the risk of occurrence and
progression of knee osteoarthritis: a 3-year follow-up of the
ROAD study. Osteoarthritis Cartilage 2012;20:1217e26.
[120] Metz JA, Morris CD, Roberts LA, McClung MR, McCarron DA.
Blood pressure and calcium intake are related to bone den-
sity in adult males. Br J Nutr 1999;81:383e8.
[121] Lethbridge-Cejku M, Tobin JD, Scott Jr WW, Reichle R,
Roy TA, Plato CC, et al. Axial and hip bone mineral density
and radiographic changes of osteoarthritis of the knee: data
from the Baltimore Longitudinal Study of Aging. J Rheumatol
1996;23:1943e7.
[122] Vestergaard P, Rejnmark L, Mosekilde L. Hypertension is a
risk factor for fractures. Calcif Tissue Int 2009;84:103e11.
[123] Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA,
Strotmeyer ES, Ensrud KE, et al. Association of BMD and FRAX
score with risk of fracture in older adults with type 2 dia-
betes. JAMA 2011;305:2184e92.
[124] Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in
patients with diabetes mellitus. J Bone Miner Res 2007;22:
1317e28.
[125] Wen CY, Chen Y, Tang HL, Yan CH, Lu WW, Chiu KY. Bone loss
at subchondral plate in knee osteoarthritis patients with
hypertension and type 2 diabetes mellitus. Osteoarthritis
Cartilage 2013;21:1716e23.
